Page 2 - Stempoint Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stempoint Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stempoint Capital Today - Breaking & Trending Today

AC Immune Announces Pricing of Underwritten Offering of

Published: December 15, 2023

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the...

Source: globenewswire.com

AC Immune Announces Pricing of Underwritten Offering of Common Shares

Published: December 15, 2023

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The Company expects the gross proceeds from the offering, before deducting the underwriting

Source: yahoo.com

Tourmaline Bio Announces Closing of Merger with Talaris

Published: October 19, 2023

Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular...

Source: globenewswire.com

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement - Talaris Therapeutics (NASDAQ:TALS)

Published: June 22, 2023

Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline's anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD)

Source: benzinga.com